Biomm

Biomm Intangible Assets

The Intangible Assets of Biomm (BIOM3.SA) as of Nov 12, 2026 is 45.72 M BRL. In the previous year, Intangible Assets was 41.24 M BRL — a change of 10.85% (higher).

Intangible Assets

45.72 MBRL

YoY

10.85%

Last updated:

Intangible Assets of Biomm is 2024 45.72 M BRL. Intangible Assets of Biomm was 2023 41.24 M BRL. It decreases by 10.85% higher compared to the previous year.

The Biomm Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2017
29.65 M BRL
Jan 1, 2018
29.99 M BRL
Jan 1, 2019
63.36 M BRL
Jan 1, 2020
58.62 M BRL
Jan 1, 2021
55.58 M BRL
Jan 1, 2022
48.33 M BRL
Jan 1, 2023
41.24 M BRL
Jan 1, 2024
45.72 M BRL
The Biomm Intangible Assets history
YEARIntangible AssetsYoY
45.72 MBRL+10.85%
41.24 MBRL-14.67%
48.33 MBRL-13.04%
55.58 MBRL-5.19%
58.62 MBRL-7.49%
63.36 MBRL+111.28%
29.99 MBRL+1.14%
29.65 MBRL+0.85%
29.40 MBRL+4.26%
28.20 MBRL—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomm Stock analysis

What does Biomm do? Biomm SA generates revenue through the development and licensing of technology for producing human insulin and other recombinant proteins. The company's patented technology, protected in multiple regions, is used by pharmaceutical firms to manufacture therapeutic proteins for drugs and biopharmaceuticals. Its subsidiaries Biomm International Inc, Biomm Middle East Inc, and Biomm Russia Ltd support global operations. The firm also develops production processes for enzymes used in biomass hydrolysis and bio-fuel manufacturing, targeting industrial applications in renewable energy sectors. The primary buyers of Biomm SA's technology are pharmaceutical companies seeking to produce therapeutic proteins. These firms license the company's patented insulin production methods to integrate into their drug manufacturing processes. The enzyme production technology is sold to companies in the bio-fuel industry, particularly those involved in biomass conversion for renewable energy. Biomm SA's focus on recombinant protein production and bio-fuel applications positions it within the biotechnology and renewable energy markets. The company's business model relies on technology licensing fees and sales of proprietary production processes. Insulin production technology, protected by international patents, forms a significant revenue stream. Enzyme technology for biomass hydrolysis and bio-fuel manufacturing provides additional income from industrial clients. Biomm SA's subsidiaries facilitate international market access, enabling the company to serve global clients across pharmaceutical and renewable energy sectors. Biomm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomm stock

Intangible Assets of Biomm is 45.72 M BRL in 2024.

Intangible Assets of Biomm changed from 41.24 M BRL to 45.72 M BRL, representing a 10.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Biomm since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's BRL is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Biomm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biomm

All Key Metrics — Biomm